Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

November 20, 2024
By Roman Fabbricatore
Fact checked by" Gina Mauro
News
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended the approval of repotrectinib (Augtyro) for the treatment of adult patients with advanced ROS1-positive non–small cell lung cancer (NSCLC) and adult and pediatric patients aged 12 years and older with advanced NTRK fusion–positive solid tumors, according to a news release from the drug’s developer, Bristol Myers Squibb.1

The NTRK fusion–positive indication is also specific to those who have received a prior NTRK inhibitor or have not received a prior NTRK inhibitor and therapies that do not target NTRK provide limited clinical benefit, or have been exhausted.

The recommendation was supported by results from the phase 1/2 TRIDENT-1 trial (NCT03093116) and the phase 1/2 CARE trial (NCT04094610). In each study, repotrectinib elicited durable activity and robust responses in adult or pediatric patients, respectively, with advanced ROS1-positive NSCLC and advanced NTRK-positive solid tumors.

“Patients in the [European Union] with ROS1-positive non–small cell lung cancer and NTRK-positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” Joseph Fiore, global program lead for repotrectinib and vice president of Bristol Myers Squibb, stated in the press release.1 “We look forward to the [European Commission’s] upcoming decision and to potentially bringing this next-generation treatment to patients with tumors harboring ROS1 or NTRK fusions in the [European Union].”

Repotrectinib received FDA approval in November 2023 for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC, based on data from the phase 1/2 TRIDENT-1 trial.2

Repotrectinib additionally received accelerated approval in June 2024 as a treatment for patients 12 years and older with locally advanced or metastatic solid tumors that are unsuitable for surgical resection and harbor an NTRK gene fusion based on data from the phase 1/2 TRIDENT-1 and CARE trials.3

TRIDENT-1 Trial

Findings published in The New England Journal of Medicine show that among patients with ROS1 fusion–positive NSCLC who had not received a prior ROS1 inhibitor (n = 71), 56 reported a confirmed response (79%; 95% CI, 68%-88%), including 7 complete responses (CRs) and 49 partial responses (PRs).4 The median time to response for this patient population was 1.8 months (range, 0.9-5.6) and the median duration of response (DOR) was 34.1 months (95% CI, 25.6-not estimable [NE]).

Furthermore, of the 56 patients who had previously received a ROS1 TKI, 21 (38%; 95% CI, 25%-52%) had confirmed responses, including 3 CRs and 18 PRs. Additionally, the median time to response was 1.8 months (range, 1.6-3.6) and the median DOR was 14.8 months (95% CI, 7.6-NE).

In TRIDENT-1, patients received 160 mg of repotrectinib once daily for 14 days followed by 160 mg twice daily. The phase 2 portion’s primary end point was confirmed ORR as assessed by blinded independent central review. Secondary end points included DOR, clinical benefit, and safety.

The most common treatment-related adverse effect (TRAE) was dizziness (58% any-grade; 3% grade 3 or higher). Additionally, 3% of patients discontinued treatment due to TRAEs, 35% had a TRAE leading to dose reduction, and 35% had a TRAE leading to dose interruption.

CARE Study

The phase 1/2 CARE study is evaluating the safety, tolerability, pharmacokinetics, and clinical activity of repotrectinib in pediatric and young adult patients with advanced or metastatic solid tumors harboring ALK, ROS1, or NTRK1-3 alterations.5

The phase 1 portion’s primary end points include dose-limiting toxicities and the recommended phase 2 dose. Secondary end points include ORR, clinical benefit rate (CBR), time to response (TTR), DOR, and intracranial ORR. The phase 2 portion primary end point is ORR. Secondary end points will include CBR, TTR, DOR, intracranial ORR, progression-free survival, and overall survival.

References

  1. Bristol Myers Squibb receives positive CHMP opinion for repotrectinib for the treatment of advanced ROS1-positive non-small cell lung cancer and advanced NTRK-positive solid tumors. News release. Bristol Myers Squibb. November 15, 2024. Accessed November 19, 2024. https://tinyurl.com/35nr46p9
  2. FDA approves repotrectinib for ROS1-positive non-small cell lung cancer. News release. FDA. November 15, 2023. https://tinyurl.com/327fb6eb
  3. U.S. Food and Drug Administration accepts for priority review Bristol Myers Squibb’s application for Augtyro (repotrectinib) for the treatment of patients with NTRK-positive locally advanced or metastatic solid tumors. News release. Bristol Myers Squibb. February 14, 2024. https://tinyurl.com/3csv92ts
  4. Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer. N Engl J Med. 2024:390(2):118-131. doi:10.1056/NEJMoa2302299
  5. A study of repotrectinib in pediatric and young adult subjects harboring ALK, ROS1, OR NTRK1-3 alterations. ClinicalTrials.gov. Updated November 13, 2024. Accessed November 19, 2024. https://tinyurl.com/bdad9m7h
Recent Videos
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Related Content
Advertisement

Amivantamab/Chemo Sustains Efficacy Despite Osimertinib Resistance in EGFR-Mutated NSCLC

Amivantamab/Chemo Sustains Efficacy Despite Osimertinib Resistance in EGFR-Mutated NSCLC

Ariana Pelosci
May 31st 2025
Article

Amivantamab/chemotherapy remained efficacious regardless of the osimertinib resistance mechanism for patients with EGFR-mutated NSCLC.


The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.


Developers Withdraw BLA for HER3-DXd in Advanced EGFR-Mutant NSCLC

Developers Withdraw BLA for HER3-DXd in Advanced EGFR-Mutant NSCLC

Tim Cortese
May 29th 2025
Article

After a lack of significant topline overall survival data from the phase 3 HERTHENA-Lung02 trial, the application for HER3-DXd in NSCLC was withdrawn.


Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.


Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.

High-Dose CCRT Plus Durvalumab May Be Safe, Efficacious in Stage III NSCLC

Roman Fabbricatore
May 28th 2025
Article

Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.


The belantamab mafodotin regimens earned approval in Japan from the Ministry of Health, Labour and Welfare in May 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

CHMP Recommends Approval of Belantamab Mafodotin Combos in Multiple Myeloma

Russ Conroy
May 23rd 2025
Article

The European Commission is expected to approve the belantamab mafodotin combinations for this multiple myeloma population in the third quarter of 2025.

Related Content
Advertisement

Amivantamab/Chemo Sustains Efficacy Despite Osimertinib Resistance in EGFR-Mutated NSCLC

Amivantamab/Chemo Sustains Efficacy Despite Osimertinib Resistance in EGFR-Mutated NSCLC

Ariana Pelosci
May 31st 2025
Article

Amivantamab/chemotherapy remained efficacious regardless of the osimertinib resistance mechanism for patients with EGFR-mutated NSCLC.


The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.


Developers Withdraw BLA for HER3-DXd in Advanced EGFR-Mutant NSCLC

Developers Withdraw BLA for HER3-DXd in Advanced EGFR-Mutant NSCLC

Tim Cortese
May 29th 2025
Article

After a lack of significant topline overall survival data from the phase 3 HERTHENA-Lung02 trial, the application for HER3-DXd in NSCLC was withdrawn.


Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.


Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.

High-Dose CCRT Plus Durvalumab May Be Safe, Efficacious in Stage III NSCLC

Roman Fabbricatore
May 28th 2025
Article

Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.


The belantamab mafodotin regimens earned approval in Japan from the Ministry of Health, Labour and Welfare in May 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

CHMP Recommends Approval of Belantamab Mafodotin Combos in Multiple Myeloma

Russ Conroy
May 23rd 2025
Article

The European Commission is expected to approve the belantamab mafodotin combinations for this multiple myeloma population in the third quarter of 2025.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.